Blood Pressure and Heart Rate Monitoring for Propranolol Therapy
For uncomplicated, healthy, full-term infants >4 weeks old with normal birthweight and established feeding, BP and HR monitoring is NOT routinely needed between appointments if the infant is well. 1
Initial Assessment Requirements
Before starting propranolol, you must:
- Measure baseline BP and HR to establish they are within normal range for age
- Perform cardiovascular examination (auscultation, peripheral pulses)
- Check for contraindications (abnormal BP/HR is a relative contraindication requiring specialist involvement) 1
Normal ranges by age:
Heart Rate (beats/min):
- Neonate (<28 days): 100-205 awake, 90-160 sleeping
- Infant (1-12 months): 100-190 awake, 90-160 sleeping 1
Blood Pressure (mmHg):
- Neonate (96h): 67-84 systolic, 35-53 diastolic
- Infant (1-12 months): 72-104 systolic, 37-56 diastolic 1
When Monitoring IS Required
Post-first dose monitoring (2-4 hours with BP/HR every 30 minutes) is needed for: 1
- Infants <4 weeks old
- Preterm infants
- Low weight/faltering growth
- Feeding difficulties
- Comorbidities (cardiac, respiratory, metabolic, neurological disorders, hyperinsulinism, history of hypoglycemia)
- Suspected PHACES syndrome (segmental facial hemangiomas)
During Ongoing Treatment
The British Society for Paediatric Dermatology consensus explicitly states: "BP and HR do not need to be monitored between appointments if the infant is well." 1 This is a Grade A recommendation from 2018.
Clinical Context:
Research supports this approach. A prospective study of 105 full-term infants found that while propranolol caused a mean 5 mmHg decrease in systolic BP, no clinically significant hypotension occurred, and BP monitoring during long-term therapy was deemed unnecessary 2. Another study of 78 hospitalized patients showed statistically significant but clinically insignificant decreases in BP and HR that remained above lower limits of normal 3.
Important Caveats:
You should counsel parents to:
- Hold doses during diminished oral intake, vomiting, or acute illness (to prevent hypoglycemia and excessive hypotension) 4
- Administer with or after feeding 4
- Monitor for lethargy or other concerning symptoms
Routine follow-up visits should occur every 2-3 months for stable patients, at which time BP/HR can be reassessed 1
Special Populations Requiring Closer Monitoring:
For high-risk patients (PHACES syndrome with cerebrovascular abnormalities), use the lowest effective dose, administer three times daily to minimize abrupt BP changes, and consider co-management with pediatric neurology 4
Bottom line: The evidence strongly supports that routine BP/HR monitoring between appointments is unnecessary for healthy infants on stable propranolol doses. The key is proper parent education about when to hold doses and appropriate interval follow-up visits.